Genomic Vision Correlations
| G09 Stock | EUR 707.37 3.80 0.53% |
The current 90-days correlation between Genomic Vision Socit and ATRYS HEALTH SA is 0.07 (i.e., Significant diversification). The correlation of Genomic Vision is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Genomic Vision Correlation With Market
Average diversification
The correlation between Genomic Vision Socit and DJI is 0.17 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Genomic Vision Socit and DJI in the same portfolio, assuming nothing else is changed.
Genomic |
The ability to find closely correlated positions to Genomic Vision could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Genomic Vision when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Genomic Vision - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Genomic Vision Socit to buy it.
Moving together with Genomic Stock
Moving against Genomic Stock
Related Correlations Analysis
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Genomic Stock performing well and Genomic Vision Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Genomic Vision's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| A2T | 1.64 | (0.18) | 0.00 | (1.93) | 0.00 | 3.81 | 11.33 | |||
| NAH | 1.89 | (0.26) | 0.00 | (0.28) | 0.00 | 3.85 | 13.49 | |||
| 3LN | 1.22 | 0.63 | 0.39 | 4.25 | 0.69 | 3.31 | 11.19 | |||
| CBW | 2.44 | 0.30 | 0.07 | 0.65 | 2.94 | 6.02 | 29.67 | |||
| PPB | 1.76 | 0.46 | 0.18 | 0.89 | 1.80 | 4.04 | 14.30 | |||
| BME | 1.72 | 0.19 | 0.00 | (0.29) | 3.01 | 5.63 | 26.62 | |||
| HT0 | 1.16 | 0.15 | 0.03 | 1.47 | 1.21 | 2.50 | 5.62 |
Be your own money manager
Our tools can tell you how much better you can do entering a position in Genomic Vision without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Share Portfolio Now
Share PortfolioTrack or share privately all of your investments from the convenience of any device |
| All Next | Launch Module |
Genomic Vision Corporate Management
Elected by the shareholders, the Genomic Vision's board of directors comprises two types of representatives: Genomic Vision inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genomic. The board's role is to monitor Genomic Vision's management team and ensure that shareholders' interests are well served. Genomic Vision's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genomic Vision's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Emilie Chataignier | Member Board | Profile | |
| Beth Jacobs | Independent Member of the Supervisory Board | Profile | |
| Isabelle Racamier | Independent Chairman of the Supervisory Board | Profile | |
| Tamar Saraga | Independent Member of the Supervisory Board | Profile | |
| Stephane Verdood | Member of the Supervisory Board | Profile | |
| Elisabeth Ourliac | Independent Vice Chairwoman of the Supervisory Board | Profile |